Back to top
more

Agios Pharmaceuticals (AGIO)

(Delayed Data from NSDQ)

$31.67 USD

31.67
539,208

-0.14 (-0.44%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $31.68 +0.01 (0.03%) 7:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (152 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for AGIO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Agios Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 777 783 1,020 573 565
Receivables 3 2 4 25 15
Notes Receivable 0 0 0 0 0
Inventories 19 8 0 15 7
Other Current Assets 35 39 40 24 24
Total Current Assets 834 833 1,064 637 612
Net Property & Equipment 15 23 29 32 31
Investments & Advances 29 314 266 98 153
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 4 4 3 1 0
Total Assets 937 1,239 1,438 853 891
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 10 19 17 27 22
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 43 30 32 60 53
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 11
Total Current Liabilities 68 63 60 94 93
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 51
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 1
Other Non-Current Liabilities 1 3 0 261 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 126 138 146 453 250
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 2,437 2,386 2,334 2,243 2,156
Retained Earnings -823 -471 -239 -1,843 -1,516
Other Equity 0 -13 -1 0 0
Treasury Stock 802 802 802 0 0
Total Shareholder's Equity 811 1,101 1,292 400 641
Total Liabilities & Shareholder's Equity 937 1,239 1,438 853 891
Total Common Equity 811 1,101 1,292 400 641
Shares Outstanding 55.80 54.90 54.30 69.30 58.80
Book Value Per Share 14.53 20.05 23.79 5.76 10.89

Fiscal Year End for Agios Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 777 647 703 739
Receivables NA 3 1 2 2
Notes Receivable NA 0 0 0 0
Inventories NA 19 17 16 11
Other Current Assets NA 35 38 37 39
Total Current Assets NA 834 704 757 792
Net Property & Equipment NA 15 17 20 21
Investments & Advances NA 29 225 244 272
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 4 4 4 4
Total Assets NA 937 1,007 1,085 1,151
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 10 13 12 9
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 43 30 29 22
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 68 58 55 45
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 1 1 1
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 126 120 121 115
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 2,437 2,422 2,411 2,399
Retained Earnings NA -823 -727 -635 -552
Other Equity NA 0 -6 -9 -8
Treasury Stock NA 802 802 802 802
Total Shareholder's Equity NA 811 887 964 1,037
Total Liabilities & Shareholder's Equity NA 937 1,007 1,085 1,151
Total Common Equity 0 811 887 964 1,037
Shares Outstanding 56.20 55.80 55.80 55.70 55.50
Book Value Per Share 0.00 14.53 15.89 17.31 18.68